Nicolaides received his BSc in biology at St. Joseph’s University, and his PhD in human genetics at Thomas Jefferson University, then continued his training as a fellow in oncology at Johns Hopkins University. He won Ernst & Young’s 2007 Entrepreneur of the Year award for the greater Philadelphia region.
Amaresh Basu, Peter Longo, Robin (Rob) Ferree, Christiaan De Wilde, Frank Morich, Nicholas Nicolaides
Chemicon Executive Joins MicroIslet as R&D Vice President
Amaresh Basu has been named vice president of research and development of MicroIslet, a San Diego developer of diabetes therapeutics.
Basu previously served as director of process sciences and project management at Chemicon/Upstate, a division of Millipore, where he managed bulk reagents, custom projects, manufacturing, and quality control processes. Before joining Chemicon in 2003, he held positions with Galileo Pharmaceuticals, Ancile Pharmaceuticals, and Trega Biosciences (formerly Houghten Pharmaceuticals). Earlier he established high throughput screening for HIV drugs as a senior scientist at the Upjohn Company.
Basu received his PhD in biochemistry from University of Poona, India, and conducted a post-doctoral fellowship in cancer and HIV research in Memorial Sloan-Kettering Cancer Center in New York. He has held academic positions in the department of biochemistry and molecular biology at UMDNJ-New Jersey Medical School.
Connecticut Innovations Promotes Acting Director to President and Executive Director
Peter Longo, acting executive director and deputy director of Connecticut Innovations, has beenappointed by its board of directors as president and executive director of the Rocky Hill-based, quasi-public technology investment organization.
Longo joined CI in 1995 as investment accounting director, and advanced to the comptroller position two years later. In 1999 Longo joined CI’s investment staff, assuming responsibility for the origination and execution of deals. Longo was named executive vice president and chief investment officer in February 2006, overseeing the closing of 11 deals, of which five were with companies relocating to Connecticut.
This past year Longo oversaw the development and launch of CI’s pre-seed support services program and $2 million seed investment fund.
Longo, a certified public accountant and chartered financial analyst, lives in Terryville, Conn. He earned a BSc degree from the University of Connecticut and his MBA from the University of Hartford.
Hagerstown-Washington County EDC Names a New Deputy Director
Robin (Rob) Ferree, business development specialist with the Hagerstown-Washington County [Md.] Economic Development Commission, has been promoted to deputy director of the EDC by the Washington County board of commissioners. In his expanded role, Ferree will coordinate the agency’s marketing and public relations functions while continuing to oversee the EDC's business development efforts as he has since joining the agency in October 2004.
Ferree has a business marketing/management degree from James Madison University. He had extensive private industry experience, including 20 years with Grove Worldwide, where he was vice president, International Sales and Government Marketing.
Belgian Biotech Innogenetics Names Temporary CEO as Predecessor Resigns
Christiaan De Wilde has been named temporary CEO of Innogenetics, a Ghent, Belgium, biotech company that halted development of a vaccine against liver disease last month. De Wilde, who had been the company’s CFO, succeeds Frank Morich who resigned from the company “to pursue other interests,” Innogenetics said in a press release.
Morphotek Executive Named Non-Executive Chairman of the Board
Nicholas Nicolaides, president and CEO of Morphotek, has been named non-executive chairman of the board of directors of TransMolecular, a biotechnology company focused on targeted therapies for cancer. Nicolaides is a co-founder of Morphotek, a biopharmaceutical company specializing in the development of protein and antibody products for treating cancer, inflammation and infectious disease.
Before joining Morphotek in 2000, Nicolaides was director of research at Magainin Pharmaceuticals, where his research focused on the development of bio-therapeutics to treat respiratory disease.